CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 18:55:04 28/06/2024 BST | ||
| 15.19 EUR | +0.86% |
|
| Current month | +17.75% | ||
| 1 month | +21.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 15.19 | +0.86% |
| 27/06/24 | 15.06 | +0.80% |
| 26/06/24 | 14.94 | +1.01% |
| 25/06/24 | 14.79 | -1.99% |
| 24/06/24 | 15.09 | +3.93% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 06:55 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GF8 |
| ISIN | DE000VU8GF81 |
| Date issued | 13/06/2023 |
| Strike | 315.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.12 € |
|---|---|
| Lowest since issue | 4.17 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
